Loss of β-cell mass is posited to occur gradually over a long period of time in preclinical type 1 diabetes mellitus, as the first signs of β-cell autoimmunity generally emerge several years before clinical presentation. This concept has recently been challenged by observations of acute loss of β-cell mass in late-phase preclinical disease.
